- Home
- WPM vs ARGX Comparison
WPM vs ARGX Comparison
Compare WPM & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPM
- ARGX
- Stock Information
- Founded
- WPM 2004
- ARGX 2008
- Country
- WPM Canada
- ARGX Netherlands
- Employees
- WPM N/A
- ARGX N/A
- Industry
- WPM Precious Metals
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WPM Basic Materials
- ARGX Health Care
- Exchange
- WPM Nasdaq
- ARGX Nasdaq
- Market Cap
- WPM 43.4B
- ARGX 51.1B
- IPO Year
- WPM 2004
- ARGX 2017
- Fundamental
- Price
- WPM $96.50
- ARGX $832.35
- Analyst Decision
- WPM Buy
- ARGX Strong Buy
- Analyst Count
- WPM 6
- ARGX 17
- Target Price
- WPM $124.83
- ARGX $866.53
- AVG Volume (30 Days)
- WPM 2.6M
- ARGX 376.8K
- Earning Date
- WPM 11-06-2025
- ARGX 10-30-2025
- Dividend Yield
- WPM 0.67%
- ARGX N/A
- EPS Growth
- WPM 37.90
- ARGX N/A
- EPS
- WPM 1.74
- ARGX 23.27
- Revenue
- WPM $1,662,398,000.00
- ARGX $3,683,281,000.00
- Revenue This Year
- WPM $55.61
- ARGX $85.93
- Revenue Next Year
- WPM $3.00
- ARGX $35.17
- P/E Ratio
- WPM $55.58
- ARGX $33.14
- Revenue Growth
- WPM 46.79
- ARGX 92.98
- 52 Week Low
- WPM $55.47
- ARGX $510.06
- 52 Week High
- WPM $114.36
- ARGX $855.46
- Technical
- Relative Strength Index (RSI)
- WPM 41.96
- ARGX 62.13
- Support Level
- WPM $94.28
- ARGX $749.75
- Resistance Level
- WPM $98.72
- ARGX $850.66
- Average True Range (ATR)
- WPM 3.21
- ARGX 24.01
- MACD
- WPM -0.48
- ARGX -3.37
- Stochastic Oscillator
- WPM 21.10
- ARGX 78.14
About WPM Wheaton Precious Metals Corp (Canada)
Wheaton Precious Metals Corp is a precious metal streaming company. The company metal streaming company which generates its revenue primarily from the sale of precious metals (gold, silver and palladium) and cobalt. Its reportable segment includes: Gold, Silver, Palladium, Platinum, Cobalt, and Other.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.